Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 11-Feb-21 10:00 PM View:  | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 30-Dec-20 | Gift | 15,000 | -- | -- | (< 1%) 2.75M to 2.73M | |
| 01-Dec-20 9:36 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 01-Dec-20 | Disposition (other) | 43,537 | -- | -- | (2%) 2.35M to 2.31M | |
| 04-Sep-20 9:09 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 04-Sep-20 | Disposition (other) | 1,500,000 | -- | -- | (38%) 3.9M to 2.4M | |
| 04-Sep-20 9:06 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 04-Sep-20 | Disposition (other) | 1,545,460 | -- | -- | (35%) 4.36M to 2.81M | |
| 04-Sep-20 9:09 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 04-Sep-20 | Disposition (other) | 45,460 | -- | -- | (2%) 2.4M to 2.35M | |
| 19-Aug-20 7:40 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 19-Aug-20 | Market Sale | 7,303 | $107.64 | $786,095.00 | (< 1%) 3.86M to 3.85M | |
| 19-Aug-20 7:40 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 19-Aug-20 | Market Sale Duplicate | 7,303 | $107.64 | $786,095.00 | (< 1%) 4.23M to 4.23M | |
| 19-Aug-20 7:40 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 18-Aug-20 | Market Sale | 10,197 | $110.03 | $1,121,980.00 | (< 1%) 3.87M to 3.86M | |
| 19-Aug-20 7:40 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 18-Aug-20 | Market Sale Duplicate | 10,197 | $110.03 | $1,121,980.00 | (< 1%) 4.24M to 4.23M | |
| 19-Aug-20 7:40 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 17-Aug-20 | Market Sale | 12,500 | $110.73 | $1,384,120.00 | (< 1%) 3.88M to 3.87M | |
| 19-Aug-20 7:40 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 17-Aug-20 | Market Sale Duplicate | 12,500 | $110.73 | $1,384,120.00 | (< 1%) 4.26M to 4.24M | |
| 29-May-20 4:51 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 27-May-20 | Disposition (other) | 44,903 | -- | -- | (1%) 3.93M to 3.88M | |
| 29-May-20 4:51 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 27-May-20 | Disposition (other) | 367,333 | -- | -- | (9%) 4.3M to 3.93M | |
| 29-May-20 4:51 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 27-May-20 | Disposition (other) | 412,236 | -- | -- | (9%) 4.67M to 4.26M | |
| 13-Dec-19 2:18 PM View: | Bay City Capital LLC 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 13-Dec-19 | Market Sale Duplicate | 1,200,000 | $105.47 | $126,564,000.00 | (22%) 5.38M to 4.18M | 2% |
| 13-Dec-19 2:08 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 13-Dec-19 | Market Sale | 1,200,000 | $105.47 | $126,564,000.00 | (22%) 5.38M to 4.18M | 2% |
| 26-Feb-20 5:41 PM View: | Milligan David V Director | Synta Pharmaceuticals Corp. (MDGL) | 21-Nov-18 | Market Sale | 20,000 | $112.54 | $2,250,800.00 | (100%) 20.0K to 0 | 8% |
| 23-Nov-18 8:53 PM View: | Friedman Paul A Chief Executive Officer Director | Synta Pharmaceuticals Corp. (MDGL) | 20-Nov-18 | Market Purchase | 4,000 | $117.88 | $471,520.00 | 3% 157.13K to 161.13K | 15% |
| 19-Nov-18 6:09 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 19-Nov-18 | Market Purchase | 2,000 | $124.69 | $249,387.00 | < 1% 296.07K to 298.07K | 8% |
| 26-Feb-20 6:06 PM View: | Milligan David V Director | Synta Pharmaceuticals Corp. (MDGL) | 19-Nov-18 | Market Sale | 10,000 | $131.60 | $1,316,000.00 | (33%) 30.0K to 20.0K | 21% |
| 19-Nov-18 6:26 PM View: | Friedman Paul A Chief Executive Officer Director | Synta Pharmaceuticals Corp. (MDGL) | 19-Nov-18 | Market Purchase | 4,000 | $124.00 | $496,000.00 | 3% 153.13K to 157.13K | 9% |
| 14-Nov-18 6:43 PM View: | Milligan David V Director | Synta Pharmaceuticals Corp. (MDGL) | 14-Nov-18 | Option Exercise | 10,000 | $16.46 | $164,600.00 | 50% 20.0K to 30.0K | |
| 19-Sep-18 4:25 PM View: | Milligan David V Director | Synta Pharmaceuticals Corp. (MDGL) | 18-Sep-18 | Option Exercise | 20,000 | $9.45 | $189,000.00 | 100% 0 to 20.0K | |
| 12-Jun-18 9:02 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale | 274,092 | $287.46 | $78,790,496.00 | (5%) 5.65M to 5.38M | 53% |
| 12-Jun-18 8:50 PM View: | Bay City Capital LLC Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale | 280,000 | $287.46 | $80,488,800.00 | (5%) 5.66M to 5.38M | 53% |
| 13-Jun-18 3:53 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale | 2,142 | $287.46 | $615,739.00 | (5%) 43.81K to 41.67K | 53% |
| 12-Jun-18 8:56 PM View: | Friedman Paul A Chief Executive Officer Director | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale Duplicate | 73,526 | $287.46 | $21,135,800.00 | (10%) 729.07K to 655.54K | 53% |
| 13-Jun-18 3:53 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Option Exercise | 7,957 | $86.64 | $689,409.00 | 18% 43.81K to 51.77K | |
| 12-Jun-18 9:02 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale | 5,908 | $287.46 | $1,698,310.00 | < 1% 5.65M to 5.65M | (53%) |
| 13-Jun-18 3:53 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Option Sale | 7,957 | $287.46 | $2,287,320.00 | (15%) 51.77K to 43.81K | 53% |
| 12-Jun-18 8:55 PM View: | Taub Rebecca Chief Medical Officer, EVP R&D Director | Synta Pharmaceuticals Corp. (MDGL) | 11-Jun-18 | Market Sale | 73,526 | $287.46 | $21,135,800.00 | 13% 582.01K to 655.54K | (53%) |
| 24-Aug-17 4:04 PM View: | Levy Richard S Director | Synta Pharmaceuticals Corp. (MDGL) | 23-Aug-17 | Market Purchase | 2,000 | $16.12 | $32,235.90 | 28% 7.1K to 9.1K | 739% |
| 23-Aug-17 4:03 PM View: | Levy Richard S Director | Synta Pharmaceuticals Corp. (MDGL) | 22-Aug-17 | Market Purchase | 3,550 | $16.12 | $57,209.10 | 100% 3.55K to 7.1K | 740% |
| 22-Aug-17 4:05 PM View: | Levy Richard S Director | Synta Pharmaceuticals Corp. (MDGL) | 21-Aug-17 | Market Purchase | 3,550 | $15.88 | $56,358.30 | 100% 0 to 3.55K | 752% |
| 22-Jul-16 5:23 PM View: | Schor Chen Former President and CEO Director | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Payment of Exercise | 14,250 | $9.48 | $135,090.00 | (28%) 51.43K to 37.18K | |
| 26-Jul-16 5:26 PM View: | Friedman Paul A Chief Executive Officer Director | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 143,703 | -- | -- | 100% 0 to 143.7K | |
| 26-Jul-16 5:55 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 5,657,850 | -- | -- | 1911% 296.07K to 5.95M | |
| 22-Jul-16 5:22 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Payment of Exercise | 8,548 | $9.48 | $81,035.00 | (31%) 27.86K to 19.31K | |
| 22-Jul-16 5:18 PM View: | Rieder Wendy E Former SVP, Gen. Counsel | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Payment of Exercise | 8,550 | $9.48 | $81,054.00 | (33%) 26.28K to 17.73K | |
| 26-Jul-16 5:25 PM View: | Taub Rebecca Chief Medical Officer, EVP R&D Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 729,066 | -- | -- | 100% 0 to 729.07K | |
| 26-Jul-16 5:26 PM View: | Friedman Paul A Chief Executive Officer Director | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant Duplicate | 729,066 | -- | -- | 507% 143.7K to 872.77K | |
| 22-Jul-16 5:22 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 25,714 | -- | -- | 1200% 2.14K to 27.86K | |
| 22-Jul-16 5:23 PM View: | Schor Chen Former President and CEO Director | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 42,857 | -- | -- | 500% 8.57K to 51.43K | |
| 26-Jul-16 5:25 PM View: | Taub Rebecca Chief Medical Officer, EVP R&D Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 432,872 | -- | -- | 59% 729.07K to 1.16M | |
| 26-Jul-16 5:55 PM View: | Craves Fred B Director 10% Owner | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 296,067 | -- | -- | 100% 0 to 296.07K | |
| 26-Jul-16 5:26 PM View: | Schneebaum Marc R Chief Financial Officer | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 22,969 | -- | -- | 119% 19.31K to 42.28K | |
| 22-Jul-16 5:18 PM View: | Rieder Wendy E Former SVP, Gen. Counsel | Synta Pharmaceuticals Corp. (MDGL) | 22-Jul-16 | Grant | 25,714 | -- | -- | 4543% 0.57K to 26.28K | |
| 05-Jan-16 6:32 PM View: | Morenstein Scott D Director | Synta Pharmaceuticals Corp. (MDGL) | 01-Jan-16 | Grant | 17,857 | -- | -- | 100% 0 to 17.86K | |
| 15-Dec-15 4:34 PM View: | Gollust Keith R Director | Synta Pharmaceuticals Corp. (MDGL) | 14-Dec-15 | Market Sale | 300,000 | $0.32 | $96,690.00 | (12%) 2.42M to 2.12M | (1087%) |
| 15-Dec-15 4:34 PM View: | Gollust Keith R Director | Synta Pharmaceuticals Corp. (MDGL) | 11-Dec-15 | Market Sale | 300,000 | $0.37 | $111,030.00 | (11%) 2.72M to 2.42M | (934%) |
